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Key Points
• T follicular helper phe-
notype is an indepen-
dent predictor of
response to HDACi in
peripheral T-cell
lymphoma.
• PFS showed a trend in
favor of the TFH phe-
notype, and 18% of the
TFH patients can use
HDACi as a bridge
to allogeneic
transplantation.
Histone deacetylase inhibitors (HDACi) are active agents for peripheral T-cell lymphoma
(PTCL). Anecdotally angioimmunoblastic T-cell lymphoma (AITL) appears to respond better
than PTCL–not otherwise specified (NOS) to HDACi. The new World Health Organization
classification shows that a subgroup of PTCL carries similarities in phenotype and gene
expression profiling to AITL, comparable to T follicular helper (TFH) cells. The disease might
behave similarly to AITL when treated with HDACi. We analyzed 127 patients with AITL
or PTCL-NOS treated with HDACi at relapse as a single agent or in combination. We re-
reviewed the pathology of all PTCL-NOS to identify the TFH phenotype. Patients received
HDACi at relapse as a single agent in 97 cases (76%, 59 TFH, 38 non-TFH) or in combination in
30 cases (24%, 18 TFH, 12 non-TFH) including duvelisib, lenalidomide, lenalidomide plus
carfilzomib, and pralatrexate. Seven PTCL-NOS had TFH phenotype; 2 PTCL-NOS were
reclassified as AITL. Overall response rate (ORR) was 56.5% (28.9% complete response [CR])
in TFH and 29.4% (19.6% CR) in non-TFH phenotype patients (P 5 .0035), with TFH
phenotype being an independent predictor of ORR (P 5 .009). Sixteen patients sufficiently
responded to HDACi or HDACi in combination with another agent to proceed directly to
allogeneic transplantation; 1 of 16 responded to donor lymphocyte infusion (12 TFH, 4
non-TFH). Our results, although retrospective, support that HDACi, as a single agent or in
combination, may have superior activity in TFH-PTCL compared with non-TFH PTCL. This
differential efficacy could help inform subtype-specific therapy and guide interpretation
of HDACi trials.
Introduction
Patients with relapsed or refractory peripheral T-cell lymphoma (PTCL) have poor prognosis, with
a median survival of 6 to 10 months.1,2
Romidepsin and other histone deacetylase inhibitors (HDACi) are active agents for relapsed/refractory
PTCL, achieving overall responses in around 25% of patients and median duration of response of 13
Submitted 21 May 2020; accepted 18 August 2020; published online 30 September
2020. DOI 10.1182/bloodadvances.2020002396.
For the original deidentified data, proposal for access should be e-mailed to the
corresponding author, Paola Ghione (paola.ghione@roswellpark.org). Individual
participant data will not be shared.
The full-text version of this article contains a data supplement.
© 2020 by The American Society of Hematology

















L user on 27 O
ctober 2020
to 17 months in the studies leading to their US Food and Drug
Administration approval.3-5 Histones are proteins that maintain
DNA configuration and regulate access to genes by transcription
factors via their acetylation or deacetylation. HDACi increase the
histone acetylation, which is thought to reduce the expression of
tumor suppressor genes and oncogenes.2
The recent World Health Organization (WHO) classification of
lymphoid malignancies, refined the PTCL–not otherwise specified
(NOS) category, introducing a subtype of PTCL defined as nodal
PTCL with T follicular helper phenotype (TFH).6 TFH-PTCL is
thought to share the same cell of origin as angioimmunoblastic
T-cell lymphoma (AITL),7 because it carries a similar mutational
pattern and gene expression profile that are believed to confer
sensitivity to HDACi via epigenetic regulation and other different
mechanism.8,9
Anecdotally, AITL appears to respond better than PTCL-NOS to
romidepsin.3 This trend has been shown in some clinical trials of
single-agent HDACi and combinations, but numbers have been too
small to drive conclusions.4,5,10-14 However, the registration studies
of these agents showed a tendency toward better overall response
rate (ORR) in AITL with belinostat (ORR 45.5% for AITL vs 23.3%
for PTCL-NOS)4 and superimposable results with romidepsin
(ORR 30% for AITL vs 29% for PTCL-NOS).5 Of note, all the
registration studies and most of the combination studies have been
conducted prior to the publication of the new WHO classification
where the TFH phenotype PTCL was defined.
Our hypothesis is that AITL and TFH-PTCL might respond better
to treatment with HDACi than PTCL-NOS. To explore this question,
we conducted a multicenter retrospective cohort study and evaluated
the outcomes of patients with PTCL (AITL, TFH-PTCL, and PTCL-
NOS) treated with HDACi, either in combination or as single agents,
across 6 international sites.
Methods
After approval by the institutional review boards at 6 academic
institutions, patients with relapsed/refractory PTCL who received
HDACi at relapse, either in combination or as a single agent, in the
context of a protocol or as commercial supply, were identified at
each site. Criteria to include patients were slightly different at each
site. At Memorial Sloan Kettering Cancer Center and Washington
University in St. Louis, MO, all patients receiving HDACi were
identified by the pharmacy database, and all patients treated in the
setting of relapsed/refractory PTCL were selected. At Weill Cornell
Medical College, Peter MacCallum Cancer Center, Concord
Repatriation General Hospital, and Stanford University, patients
were selected from institutional lymphoma databases. We included
in the analysis all cases that were identifiable as AITL, PTCL-NOS,
and TFH-PTCL according to the WHO classification of 2016.6 The
majority of the cases classified as PTCL-NOS were re-reviewed at
each institution to assess the TFH phenotype. When the physical
re-review was not feasible, the phenotype was reassessed by
looking at the markers’ expression on the pathology reports. This
phenotype was defined as having strong expression by immuno-
histochemistry and/or flow cytometry of at least 2 TFH markers,
among CD10, CD279 (PD1), CXCL13, ICOS, SAP, CCR5, and
BCL6.2 Pathology review was performed locally at each institution.
Cases of PTCL-NOS in which the tissue could not be reviewed and
a minimum of at least 2 markers for TFH were not included in the
report were excluded from this analysis.
Medical and pathology records were evaluated for clinical character-
istics, pathologic and radiologic data, and treatment history at each
institution. Treatment was considered to have occurred if at least 1
dose of the drug was administered. The investigators at each site
reported responses based, whenever possible (121 of 127 patients),
on the Lugano criteria applied retrospectively.15 In 6 cases, the
patients did not receive a second positron emission tomogra-
phy/computed tomography assessment. These patients had
received .3 doses of HDACi and were coded as nonresponders.
Progression-free survival (PFS) was defined as time from the
initiation of the first treatment until death or progression. Patients
undergoing allogeneic transplant right after HDACi (bridge to
transplant) were censored at the time of transplant, and transplant
was not considered an event. PFS was defined as time from
initiation of HDACi until investigator-assessed progression, death
from any cause, or date of last follow-up if in remission. Time-to-
event statistics were estimated using the Kaplan-Meier method;
differences in survival were estimated with log-rank; and differences
between groups were estimated with the Mann-Whitney U test,
Fisher’s exact test, and the logistic regression model. Follow-up
time was calculated by the reverse censoring method. Analyses
and graphs were performed with the statistical programs R,
STATA, GraphPad, and the cBioPortal.
Results
Patients
A total of 164 patients receiving HDACi between April 2005 and
January 2019 were identified from 6 institutions.
A total of 127 patients met the inclusion criteria. Thirty-seven
patients were excluded from the analysis for the following reasons:
13 patients with PTCL were not evaluable for the TFH phenotype;
5 patients had other forms of T-cell lymphoma (2 monomorphic
epitheliotrophic intestinal T-cell lymphoma, 2 hepatosplenic T-cell
lymphoma, 1 anaplastic large cell lymphoma); 7 received romidep-
sin as maintenance after autologous transplant on a clinical trial
(NCT01908777); 11 patients were treated on a clinical trial combining
romidepsin with gemcitabine and oxaliplatin (NCT02181218); and
1 patient died minutes after the infusion of HDACi from a sudden
cardiac arrest and was not evaluable. All patients relapsed after
frontline chemotherapy per the inclusion criteria of the study. Median
follow up was 31.6 months (range, 0.3-126.5 months). Characteristics
of the 127 patients at time of HDACi therapy are described in Table 1.
Ninety-seven patients were treated with single-agent romidep-
sin (n 5 84) or belinostat (n 5 13), 14 in the context of clinical
trials and 83 as commercial supply. Thirty patients were treated
with romidepsin combinations, 29 as part of a clinical trial (11
received romidepsin/duvelisib [NCT02783625],10 12 received
romidepsin/carfilzomib/lenalidomide [NCT02341014],13 6 re-
ceived romidepsin/lenalidomide [NCT01755975]12); 1 patient
received romidepsin/pralatrexate16 as commercial supply. After
pathology re-review of the PTCL-NOS cases, where it was feasible
to add Immunohistochemistry for the TFH markers, 7 patients
were classified as TFH-PTCL, and 2 patients were reclassified
as AITL.
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ORR
The ORR to HDACi as both single agent and in combination was
45.6% (32 of 127 patients, 25% complete response [CR]). When
HDACi were used as single agents, ORR was 45.3% (23 of 97
patients [23.7%CR]) and 46.6% (9 of 30 patients [30%CR]) when
used in combination. Table 2 summarizes the ORR for patients with
TFH phenotype and non-TFH phenotype in our cohort, when
treated with single agent or in combination.
To evaluate if the TFH phenotype might be an independent predictor
of response, we performed a univariate analysis of 12 variables that
might have impacted the ORR, and then a logistic regression model
of the significant variables (Table 3).
All variables were calculated at the time of relapse before HDACi
infusion, and included age, stage, extranodal involvement, perfor-
mance status (ECOG), LDH, IPI stage, autologous transplantation
as consolidation of first line therapy, response to first-line chemother-
apy (CR and partial response vs stable disease [SD] and progressive
disease [PD]), lines of treatment before HDACi, and combination vs
single agent HDACi.
After univariate analysis, 2 variables were significantly associated
to ORR: TFH phenotype and response to first-line chemother-
apy (P 5 .003 and P 5 .010, respectively). Logistic regression
demonstrated that the 2 variables have independent predic-
tive value. P value for TFH phenotype was .009 (std, 21.02;
error, 0.39).
PFS and bridge to allogeneic transplantation
Median PFS after HDACi was 4.1 months for TFH phenotype
patients and 2.1 months for non-TFH phenotype patients; log rank
P 5 .18 (hazard ratio [HR] 0.5 for TFH; 95% confidence interval
[95% CI], 0.33-0.75) (Figure 1).
Median PFS after frontline had been 7.3 months for the TFH
patients and 5.3 months for the non-TFH phenotype patients;
log rank P 5 .65 (HR 1.39 for non-TFH; 95% CI, 0.98-1.99)
(Figure 2).
For the 42 patients with TFH phenotype who responded to HDACi,
median duration of response was 7 months (range, 0.2-45 months).
The 15 patients with non-TFH PTCL who responded to HDACi
had a median duration of response of 16 months (range, 0.9-77
months).
Twenty-nine patients (23%) in this cohort underwent allogeneic
stem cell transplantation at some point after receiving HDACi,
10 (8%) with non-TFH phenotype and 19 (15%) with TFH phenotype
PTCL. Fifteen patients (12%) proceeded directly to allogeneic
transplantation after achieving a response to HDACi. One received
HDACi as a bridge to donor lymphocyte infusion. Twelve (75%) of
these patients using this bridging HDACi had a TFH phenotype
PTCL, and 4 (25%) had non-TFH phenotype PTCL (Figure 1). Of
these 16 patients, 10 are alive and 5 are also in remission at last
follow-up.
Setting a cutoff for age (TFH phenotype are 8 years older than non-
TFH, median 63 years [range, 29-83 years] vs 55 years [range,
30-81 years]; P5 .003) and excluding patients older than 75 years
at time of HDACi, a similar percentage of patients with TFH
phenotype (19 of 65, 29%) and non-TFH phenotype (10 of 46,
22%) in our population received an allogeneic transplantation
(P5 .511). Considering only transplants with romidepsin as bridge,
12 of 65 (18%) TFH-phenotype patients reached allogeneic trans-
plant and 4 of 46 (8.6%) non-TFH reached transplant (P 5 .178).
Five patients died of transplant-related complications, 1 from
Pneumocystis jirovecii pneumonia after relapsing after allogeneic
Table 1. Patients’ characteristics
Patient characteristics (N 5 127) TFH (n 5 76) Non TFH (n 5 51) P
Sex, male/female, n (%) 41 (54)/35 (46) 33 (65)/18 (35) .272
Age, median (range), y 63 (29-83) 55 (30-81) .003
Prior therapies, median (range), n 2 (1-5) 2 (1-5) .327
Time from diagnosis, median (range), mo 12 (3-157) 9 (3-152) .417
Ann Arbor, n (%)
I-II 3 (4) 6 (12) .155
III-IV 73 (96) 45 (88)
PS, n (%)
0/1 58 (76) 37 (73) .575
2 or more 12 (16) 10 (20)
Missing 6 (8) 4 (7)
LDH, n (%)
Normal 29 (38) 16 (31) .420
Elevated 34 (45) 26 (51)
Missing 13 (17) 9 (18)
IPI at HDACi start, n (%)
0-2 26 (34) 16 (31) .695
3-5 36 (47) 26 (51)
NA 14 (18) 9 (18)
Type of treatment, n (%)
Commercial 50 (66) 34 (67) .918
Investigational 26 (34) 17 (33)
IPI, International Prognostic Index; LDH, lactate dehydrogenase.
Table 2. Response to romidepsin as single agent or combinations in TFH vs non-TFH phenotype relapsed/refractory PTCL
Response
TFH (n 5 76) Non-TFH (n 5 51)
ORR, n/total (%) CR, n/total (%) ORR, n/total (%) CR, n/total (%) P*
Overall (n 5 127) 43/76 (56.5) 22/76 (28.9) 15/51 (29.4) 10/51 (19.6) .0035
Single agent (n 5 97) 32/59 (54.2) 15/59 (25.4) 12/38 (31.5) 8/38 (21.0) .0371
Combinations (n 5 30) 11/18 (61.1) 7/18 (38.8) 3/12 (25.0) 2/12 (16.6) .0717
*P values have been calculated with the Fisher’s exact test.
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transplantation. Median overall survival for this population was
12 months (range, 4-83 months)
TFH patients
ORR in the TFH-PTCL group (n 5 7) was 71% (3 CR, 2 partial
response, 1 SD, and 1 PD) (Figure 3). Four patients were treated
with romidepsin or belinostat as single agent (3 responded, 1
achieved SD); 3 patients were included in romidepsin combinations
protocols (2 responded, 1 had PD). Patients with TFH-PTCL
had higher ORR when compared with PTCL-NOS (71% vs 29%,
P 5 .041), but had similar ORR when compared with those with
AITL (71% vs 56%, P 5 .693) (Figure 3).
Mutational analysis
MSK IMPACT-heme 400-genes targeted sequencing17 was per-
formed with modification of a previously published method to
include genes specifically mutated in hematological malignancies.
The analysis was performed with a paired normal DNA sample at the
time of relapse/refractoriness in 28 patients, including 10 with non-
TFH and 18 with TFH phenotype PTCL. Of the TFH phenotype
PTCL, 14 responded to HDACi and 4 had SD or PD.
Table 3. Logistic regression
Variable (at time of HDACi start)
Univariate models Multivariate model using significant univariate variables
Odds ratio P Estimate std Error z value Pr (>|z|)
TFH phenotype 0.322 .003 21.026 0.393 22.608 0.009
Age 0.640 .283
Stage 0.948 1.000




AutoSCT consolidation in first line 0.910 .910
Response to first-line chemotherapy 2.893 .011 0.926 0.4297 2.166 0.030
Relapse within 1 y from first-line chemotherapy 1.486 .335
Lines of therapy before HDACi 0.079 .079
Combination HDACi vs single agent 0.949 .000
Bold indicates statistically significant P values.
AutoSCT, autologous stem cell transplantation; ECOG, Eastern Cooperative Oncology Group.
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Figure 1. PFS of relapsed/refractory TFH vs non-TFH
phenotype PTCL after HDACi. PFS was 4.1 months for
TFH phenotype patients and 2.1 months for non-TFH pheno-
type patients; log rank P 5 .18 (HR 0.5 for TFH; 95% CI,
0.33-0.75). For patients undergoing allogeneic stem cell
transplantation, time on the curve was censored at the time
of transplant.
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Among the non-TFH phenotype PTCL, 4 responded to HDACi and
6 had SD or PD. Figure 4 shows a detail of the targeted sequencing
results, all performed at Memorial Sloan Kettering Cancer Center,
with the genes ordered for frequency of mutations, divided among
responders and nonresponders to HDACi using the cBioPortal.18
All 10 PTCL-NOS among these 28 cases were re-reviewed by
pathology.
In this small group of patients, typical AITL mutations (TET2, and/or
DNMT3A, and/or RHOA) were present in 15 of 18 of patients
responding to HDACi (83%) and in 4 of 10 nonresponding to
HDACi (40%) (P5 .034). Responders to HDACi were AITL or TFH
PTCL in 14 of 18 cases (77%) and 4 of 10 of the nonresponders
(40%) (P 5 .097). Two patients with histopathological diagnosis of
AITL did not have typical AITL mutations, and both had progression
of disease despite HDACi. Two patients with PTCL-NOS had
at least 1 typical AITL mutation (RHOA and DNMT3A), 1 achieved
a CR, the other had SD.
Patients with mutations that are thought to confer resistance to
chemotherapy, like DNMT3AR882X (n 5 4; 3 AITL, 1 TFH-PTCL)19
and TP53 (4 patients) all responded to HDACi. In our cohort, 4 of
18 (22.2%) relapsed/refractory TFH-PTCL and AITL patients had
DNMT3AR882X mutation. One of the 4 patients with DNMT3AR882X
had previously responded to chemotherapy consolidated with autolo-
gous stem cell transplantation but was found to have relapsed at
restaging post-AutoSCT. Additional details of this population
are present in the supplemental Data.
1.0
Progression Free Survival




































Figure 2. PFS of relapsed/refractory TFH vs non-TFH
phenotype PTCL after front-line chemotherapy, of
which 25% underwent high-dose chemotherapy and
autologous stem cell rescue. PFS was 7.3 months for the
TFH patients and 5.3 months for the non-TFH phenotype
patients; log rank P 5 .65 (HR 1.39 for non-TFH; 95% CI,
0.98-1.99).
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PTCL. POD, progression of disease.
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Discussion
In this large retrospective study, we support the clinical observation
that treatment with HDACi appears to achieve higher responses in
patients with TFH phenotype lymphoma (AITL and TFH-PTCL) than
PTCL-NOS.
Both patients receiving HDACi as single agent and, less prominently,
those receiving HDACi combinations, showed higher percentages of
response when compared with PTCL-NOS. In our series, patients
with TFH-PTCL and AITL have similar responses and duration of
response to HDACi-based therapy.9
In the linear regression model, the TFH phenotype demonstrated
to be 1 of the only 2 variables at time of relapse that could independently
predict ORR to HDACi in our cohort. Of interest, the character-
istics of performance status, stage, LDH and the comprehensive
IPI score did not seem to influence the response to HDACi. The
second variable found to independently predict response to
HDACi was the response to frontline chemotherapy, with patients
not achieving response (with PD or SD) to chemotherapy less
frequently responding to HDACi.
Although the PFS with HDACi appears similar between TFH
and non-TFH phenotype patients, 12 (18%) patients in the TFH
subgroup vs 4 (8%) in the non-TFH phenotype group subsequently
underwent allogeneic transplantation using HDACi as a bridge
therapy, and these patients were censored at the time of transplant.
Median time from start of HDACi to allogeneic transplant was
4 months (range, 2-14 months).
The retrospective nature of our study presents several limitations.
The most evident is that the ORR and CR rate to HDACi is higher
than seen in the registration studies of romidepsin and belinostat.
This may be because of nonhomogeneous patient selection among
different academic centers, leading to enrichment of responding
patients in the dataset. Nevertheless, this kind of bias should equally
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Figure 4. Detail of all more frequent mutations found on targeted sequence IMPACT heme panel performed at time of relapse/refractoriness in 28 patients
receiving HDACi.
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receiving combinations of HDACi with other drugs. Patients
enrolled in these trials are equally distributed between TFH and
non-TFH phenotype; however, this is another factor in the higher-
than-expected ORR. Moreover, this is a cohort treated at big
academic sites, and the results might not be representative of the
general patient population.
Our limited data on targeted sequencing seem to suggest that
mutations typically found in TFH phenotype might predict re-
sponsiveness to HDACi in addition to the pathologic diagnosis
itself. These are very preliminary data on a small group of patients.
The data will require confirmation in larger cohorts.
In a prospective study of patients with AITL receiving first line
chemotherapy and lenalidomide, Lemonnier et al.19 have found that
the DNMT3AR882X mutations were associated with resistance to
chemotherapy in all 6 mutated and 64 nonmutated (9.4%) patients.
Resistance to anthracycline had similarly been reported in
DNMT3AR882X-mutated AML.20
In our cohort of relapsed/refractory patients receiving HDACi, 4 of
18 (22.2%) AITL patients were found to have the DNMT3AR882X
mutation. Three of the 4 patients in this series with DNMT3AR882X
did not respond to initial chemotherapy and 1 progressed shortly
after autologous transplantation. All 4 patients with DNMT3AR882X
subsequently responded to HDACi.
In conclusion, these data suggest that using HDACi in combination
therapies for AITL and TFH PTCL might be a particularly promising
strategy. Likewise, when designing a trial including HDACi, the
proportion of patients with TFH-phenotype PTCL may influence the
overall response to that treatment.
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